For Immunotherapy Of Cancer Articles & Analysis
138 news found
During the event, the team demonstrated their pipeline from phage construction to screening and their masterpiece in discovering PTM specific antibodies, anti-idiotype antibodies, which gives researchers an edge when looking to discover novel targets in immunotherapy, cancer, and infectious diseases. Another hot topic during the festival was the growing interest ...
The portfolio features both a tumor-naïve assay and a tumor-informed assay that are designed to help detect residual disease or early cancer recurrence and monitor for immunotherapy treatment response, providing valuable insights to inform patient management strategies. ...
ByTempus
Dedicated to the research of new immunotherapeutic vaccines in oncology and prophylactic vaccines for contagious diseases, the aim of the joint Institut Pasteur – Oncovita laboratory is to design and develop vaccine candidates through to proof of concept in humans. Oncovita and the Institut Pasteur have already been working together for several years on the construction and development of ...
ByOncoVITA
This critical information holds immense potential in unraveling immune responses, gaining insights into autoimmune diseases, advancing cancer immunotherapy, and propelling vaccine development. CD Genomics' latest enhancements in TCR-Seq technology promise to provide even more accurate and comprehensive insights into the adaptive immune system. ...
However, recent studies have shown that EBNA1 can be presented to both CD4+ and CD8+ T cells, making it a potential new target for EBV-associated cancer immunotherapy. These new reagents can be used to study herpesviruses in the laboratory and to develop assays to detect and measure herpesvirus infection. ...
Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced promising new in vivo combination data that support the potential of the company’s novel gaseous nitric oxide (gNO) therapy to treat various types of solid tumors in combination with ...
Cartherics’ initial target indication is relapsed or refractory ovarian cancer, where greater than 90 percent of tumors are TAG-72 positive. Targeting these tumors with novel cellular immunotherapies will help address the unmet need for new treatment options for ovarian cancer patients. ...
(NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced that the United States Patent and Trademark Office has issued U.S. ...
Antengene is proud to announce that the oral presentation for ATG-031 (anti-CD24 monoclonal antibody) presented at the 37th Society for Immunotherapy of Cancer Annual Meeting (SITC 2022) was selected for the SITC top 100 abstracts. ...
Her knowledge and experience will support a deeper understanding of active cancer immunotherapies in the drug discovery process provided by scientific innovation. ...
ByArdigen
(Nasdaq: “SCPS”), a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, and its pure-play immuno-oncology subsidiary, Duet BioTherapeutics, today announced that key scientific data will be will be presented at the 37th Annual Meeting and Exposition of the Society for Immunotherapy of ...
(NASDAQ: XAIR) a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced ...
Creative BioMart, a biotechnology company that offers a wide range of solutions dedicated to helping researchers and pharmaceutical companies discover and develop novel drugs in the treatment of cancer, autoimmune diseases, etc., now offers MHC solutions for cell therapy and vaccine development. ...
Therefore, inhibiting HPK1 activity serves as a promising approach for cancer immunotherapy. Currently, there is no HPK1 inhibitor approved globally. ...
CD Genomics, a world-leading company in genomic services, today announced that members of its management team would participate in the 37th Society for Immunotherapy of Cancer’s (SITC) Annual Meeting in Boston, MA, November 8-12, 2022. Details for the 37th Annual Meeting & Pre-Conference Programs (SITC 2022) The 37th Annual Meeting & ...
The data, including studies presented at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting & Pre-conference Programs in November 2021, has demonstrated that the combination of an ERK1/2 inhibitor and an immune checkpoint inhibitor (ICI) worked synergistically to produce improved efficacy in preclinical ICI-resistant in vivo mice models. ...
(“Elpiscience”), a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide, today announced it will have five poster presentations at the SITC 2022 Annual Meeting being held in Boston, Massachusetts from November 8-12. ...
(“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, today announced the appointment of Christopher Whitmore as chief financial officer. ...
Chiles Research Institute, Providence Cancer Institute, Portland, Oregon. “Currently, 70-80 percent of cancer patients with solid tumors do not achieve durable responses to T-cell checkpoint therapies alone, and people with many types of cancer have yet to benefit from the promise of this class of immunotherapy. ...
(KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the Company will present preclinical data of PMC-309, one of the Company’s first immuno-oncology drug candidates, at SITC (Society for Immunotherapy of Cancer) Annual Meeting taking place November 8-12 in Boston. ...